Evolution of therapeutic management of patients with ANCA associated vasculitis in France after licensing Rituximab use.
Antineutrophil cytoplasmic antibody-associated vasculitides
Systemic vasculitis
Journal
BMC rheumatology
ISSN: 2520-1026
Titre abrégé: BMC Rheumatol
Pays: England
ID NLM: 101738571
Informations de publication
Date de publication:
28 Apr 2024
28 Apr 2024
Historique:
received:
24
11
2023
accepted:
10
04
2024
medline:
29
4
2024
pubmed:
29
4
2024
entrez:
28
4
2024
Statut:
epublish
Résumé
In 2013, rituximab was approved in France for the treatment of ANCA-associated vasculitis (AAV). The aim of the study was to compare the treatment and health events of adult incident patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), included before rituximab approval (over 2010-2012, Group 1) and those included after rituximab approval (over 2014-2017, Group 2). Data were extracted from the French National Health Insurance database (SNDS) including outpatient health care consumption and hospital discharge forms. Comparisons between inclusion periods were performed using Wilcoxon and χ² tests. Kaplan-Meier method was used to model the duration of treatment induction, maintenance, and off-drug periods. Fine and Gray tests were used to compare treatment phase durations. A total of 694 GPA and 283 MPA patients were included in Group 1, while 668 GPA and 463 MPA patients were included in Group 2. Between the two inclusion periods, the proportions of patients treated with rituximab increased in the induction and maintenance phases whereas treatment with azathioprine declined. These proportions remained stable in the case of methotrexate, cyclophosphamide, and glucocorticoid-treated patients. Frequency of first-time hospitalized infections, diabetes and renal failure during the first year after inclusion increased for both groups. This is a retrospective study based on claims data including only 76% of people covered by health insurance in France. The period studied includes the learning phase of using rituximab. This study lacks biological data and precise quantitative analysis for the use of steroids, therefore the criteria for establishing diagnosis and therapeutic choice were unknown. Introduction of rituximab reduced the use of azathioprine without affecting the use of glucocorticoids or cyclophosphamide.
Identifiants
pubmed: 38679737
doi: 10.1186/s41927-024-00385-8
pii: 10.1186/s41927-024-00385-8
doi:
Types de publication
Journal Article
Langues
eng
Pagination
16Informations de copyright
© 2024. The Author(s).
Références
Bataille PM, Durel C-A, Chauveau D, et al. Epidemiology of granulomatosis with polyangiitis and microscopic polyangiitis in adults in France. J Autoimmun. 2022;133:102910. https://doi.org/10.1016/j.jaut.2022.102910 .
doi: 10.1016/j.jaut.2022.102910
pubmed: 36108505
Terrier B, Darbon R, Durel C-A, et al. French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides). Orphanet J Rare Dis. 2020;15:351. https://doi.org/10.1186/s13023-020-01621-3 .
doi: 10.1186/s13023-020-01621-3
pubmed: 33372616
pmcid: 7771069
Geetha D, Jefferson JA. ANCA-Associated Vasculitis: Core Curriculum 2020. Am J Kidney Dis. 2020;75:124–37. https://doi.org/10.1053/j.ajkd.2019.04.031 .
doi: 10.1053/j.ajkd.2019.04.031
pubmed: 31358311
Robson J, Doll H, Suppiah R, et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology. 2015;54:471–81. https://doi.org/10.1093/rheumatology/keu366 .
doi: 10.1093/rheumatology/keu366
pubmed: 25205825
Koening CL, von Hennigs I. Antineutrophil cytoplasmic antibody (ANCA) vasculitis: pathophysiology, diagnosis, and the evolving treatment landscape. Am J Manag Care. 2021;27:S267–76. https://doi.org/10.37765/ajmc.2021.88746 .
doi: 10.37765/ajmc.2021.88746
pubmed: 34473462
Stone JH, Merkel PA, Spiera R, et al. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. N Engl J Med. 2010;363:221–32. https://doi.org/10.1056/NEJMoa0909905 .
doi: 10.1056/NEJMoa0909905
pubmed: 20647199
pmcid: 3137658
Jones RB, Cohen Tervaert JW, Hauser T, et al. Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis. N Engl J Med. 2010. https://doi.org/10.1056/NEJMoa0909169 .
doi: 10.1056/NEJMoa0909169
pubmed: 21142534
pmcid: 3073631
Merkel PA, Niles JL, Mertz LE, et al. Long-term safety of Rituximab in Granulomatosis with Polyangiitis and in microscopic polyangiitis. Arthritis Care Res. 2021;73:1372–8. https://doi.org/10.1002/acr.24332 .
doi: 10.1002/acr.24332
Charles P, Perrodeau É, Samson M, et al. Long-term Rituximab Use to maintain remission of Antineutrophil cytoplasmic antibody–Associated Vasculitis: a Randomized Trial. Ann Intern Med. 2020;173:179–87. https://doi.org/10.7326/M19-3827 .
doi: 10.7326/M19-3827
pubmed: 32479166
Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75:1583–94. https://doi.org/10.1136/annrheumdis-2016-209133 .
doi: 10.1136/annrheumdis-2016-209133
pubmed: 27338776
Terrier B, Guillevin L. (2019) Protocole national de diagnostic et de soin des vascularites nécrosantes systémiques (périartérite noueuse et vascularites associées aux ANCA).
Sultana J, Azzopardi-Muscat N, Coleiro B, et al. Pharmacological therapy in a rare disease: challenges in the long-term management of granulomatosis with polyangiitis. Expert Opin Orphan Drugs. 2019;7:521–3. https://doi.org/10.1080/21678707.2019.1701433 .
doi: 10.1080/21678707.2019.1701433
Tuppin P, Rudant J, Constantinou P, et al. Value of a national administrative database to guide public decisions: from the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Rev DÉpidémiologie Santé Publique. 2017;65:S149–67. https://doi.org/10.1016/j.respe.2017.05.004 .
doi: 10.1016/j.respe.2017.05.004
CNAM. (2021) Méthodologie médicale de la cartographie des pathologies et des dépenses, version G8 (années 2015 à 2019, Tous Régimes).
Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus Azathioprine for maintenance in ANCA-Associated Vasculitis. N Engl J Med. 2014;371:1771–80. https://doi.org/10.1056/NEJMoa1404231 .
doi: 10.1056/NEJMoa1404231
pubmed: 25372085
Samman KN, Ross C, Pagnoux C, Makhzoum J-P. Update in the management of ANCA-Associated Vasculitis: recent developments and future perspectives. Int J Rheumatol. 2021;2021:1–14. https://doi.org/10.1155/2021/5534851 .
doi: 10.1155/2021/5534851
Thomas K, Argyriou E, Kapsala N, et al. Serious infections in ANCA-associated vasculitides in the biologic era: real-life data from a multicenter cohort of 162 patients. Arthritis Res Ther. 2021;23:90. https://doi.org/10.1186/s13075-021-02452-8 .
doi: 10.1186/s13075-021-02452-8
pubmed: 33741047
pmcid: 7980356
Thomas K, Vassilopoulos D. Infections and vasculitis. Curr Opin Rheumatol. 2017;29:17–23. https://doi.org/10.1097/BOR.0000000000000348 .
doi: 10.1097/BOR.0000000000000348
pubmed: 27662570
Garcia-Vives E, Segarra-Medrano A, Martinez-Valle F, et al. Prevalence and risk factors for major infections in patients with Antineutrophil cytoplasmic antibody–associated Vasculitis: influence on the Disease Outcome. J Rheumatol. 2020;47:407–14. https://doi.org/10.3899/jrheum.190065 .
doi: 10.3899/jrheum.190065
pubmed: 31203229
Caballero-Islas AE, Hoyo-Ulloa I, García-Castro A, Hinojosa-Azaola A. Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a retrospective cohort study with a clinical phenotype approach. Rheumatol Int. 2020;40:1657–66. https://doi.org/10.1007/s00296-020-04661-x .
doi: 10.1007/s00296-020-04661-x
pubmed: 32728838
Biedroń G, Włudarczyk A, Wawrzycka-Adamczyk K, et al. Treatment and its side effects in ANCA-associated vasculitides - study based on POLVAS registry data. Adv Med Sci. 2020;65:156–62. https://doi.org/10.1016/j.advms.2020.01.002 .
doi: 10.1016/j.advms.2020.01.002
pubmed: 31958704
Walsh M, Merkel PA, Peh C-A, et al. Plasma exchange and glucocorticoids in severe ANCA-Associated Vasculitis. N Engl J Med. 2020;382:622–31. https://doi.org/10.1056/NEJMoa1803537 .
doi: 10.1056/NEJMoa1803537
pubmed: 32053298
pmcid: 7325726
Sarica SH, Dhaun N, Sznajd J, et al. Characterizing infection in anti-neutrophil cytoplasmic antibody–associated vasculitis: results from a longitudinal, matched-cohort data linkage study. Rheumatology. 2020;59:3014–22. https://doi.org/10.1093/rheumatology/keaa070 .
doi: 10.1093/rheumatology/keaa070
pubmed: 32159801
pmcid: 7516107
Robson J, Doll H, Suppiah R, et al. Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. Ann Rheum Dis. 2015;74:177–84. https://doi.org/10.1136/annrheumdis-2013-203927 .
doi: 10.1136/annrheumdis-2013-203927
pubmed: 24243925
Boomsma MM, Stegeman CA, Kramer AB, et al. Prevalence of reduced bone mineral density in patients with anti-neutrophil cytoplasmic antibody associated vasculitis and the role of immunosuppressive therapy: a cross-sectional study. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2002;13:74–82. https://doi.org/10.1007/s198-002-8341-z .
doi: 10.1007/s198-002-8341-z
Fernández-Ávila DG, Rondón-Carvajal J, Villota-Eraso C, et al. Demographic and clinical characteristics of patients with ANCA-positive vasculitis in a Colombian University Hospital over a 12-year period: 2005–2017. Rheumatol Int. 2020;40:1283–90. https://doi.org/10.1007/s00296-020-04631-3 .
doi: 10.1007/s00296-020-04631-3
pubmed: 32564160
Seo P, Min Y-I, Holbrook JT, et al. Damage caused by Wegener’s granulomatosis and its treatment: prospective data from the Wegener’s granulomatosis Etanercept Trial (WGET). Arthritis Rheum. 2005;52:2168–78. https://doi.org/10.1002/art.21117 .
doi: 10.1002/art.21117
pubmed: 15986348
van Daalen EE, Rizzo R, Kronbichler A, et al. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis. 2017;76:1064–9. https://doi.org/10.1136/annrheumdis-2016-209925 .
doi: 10.1136/annrheumdis-2016-209925
pubmed: 27899372
Pagnoux C, Carette S, Khalidi NA, et al. Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. Clin Exp Rheumatol. 2015;33:S–77.
pubmed: 26016754
pmcid: 4525702
Charles P, Terrier B, Perrodeau É, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77:1143–9. https://doi.org/10.1136/annrheumdis-2017-212878 .
doi: 10.1136/annrheumdis-2017-212878
pubmed: 29695500
Corral-Gudino L, González-Vázquez E, Calero-Paniagua I, et al. The complexity of classifying ANCA-associated small-vessel vasculitis in actual clinical practice: data from a multicenter retrospective survey. Rheumatol Int. 2020;40:303–11. https://doi.org/10.1007/s00296-019-04406-5 .
doi: 10.1007/s00296-019-04406-5
pubmed: 31385079
Sabaté E, World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.
Pagnoux C, Fifi-Mah A. Update on maintenance therapies for ANCA-Associated Vasculitis. Curr Treat Options Rheumatol. 2021;7:112–33. https://doi.org/10.1007/s40674-021-00176-z .
doi: 10.1007/s40674-021-00176-z